XBiotech Market Capitalization from 2010 to 2025
| XBIT Stock | USD 3.82 0.02 0.53% |
Check XBiotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XBiotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 985.4 K or Selling General Administrative of 7.9 M, as well as many indicators such as Price To Sales Ratio of 14.88, Dividend Yield of 0.18 or PTB Ratio of 0.61. XBiotech financial statements analysis is a perfect complement when working with XBiotech Valuation or Volatility modules.
XBiotech | Market Capitalization |
Latest XBiotech's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of XBiotech over the last few years. It is XBiotech's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XBiotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 116.45 M | 10 Years Trend |
|
Market Cap |
| Timeline |
XBiotech Market Capitalization Regression Statistics
| Arithmetic Mean | 416,628,662 | |
| Geometric Mean | 318,977,392 | |
| Coefficient Of Variation | 66.10 | |
| Mean Deviation | 247,495,250 | |
| Median | 334,817,675 | |
| Standard Deviation | 275,400,103 | |
| Sample Variance | 75845.2T | |
| Range | 630.6M | |
| R-Value | (0.78) | |
| Mean Square Error | 31592.2T | |
| R-Squared | 0.61 | |
| Significance | 0.0003 | |
| Slope | (45,224,502) | |
| Total Sum of Squares | 1137678.2T |
XBiotech Market Capitalization History
About XBiotech Financial Statements
XBiotech shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although XBiotech investors may analyze each financial statement separately, they are all interrelated. The changes in XBiotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on XBiotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 96 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.